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ResistanceThe store-operated calciumchannels (SOCs) represent oneof themajor calcium-entry pathways innon-excitable
cells. SOCs and in particular their major components ORAI1 and STIM1 have been shown to be implicated in a
number of physiological and pathological processes such as apoptosis, proliferation and invasion. Here we
demonstrate that ORAI1 and STIM1mediate store-operated calcium entry (SOCE) in pancreatic adenocarcinoma
cell lines. We show that both ORAI1 and STIM1 play pro-survival anti-apoptotic role in pancreatic adenocarcino-
ma cell lines, as siRNA-mediated knockdown of ORAI1 and/or STIM1 increases apoptosis induced by chemother-
apy drugs 5-ﬂuorouracil (5-FU) or gemcitabine.We also demonstrate that both 5-FU and gemcitabine treatments
increase SOCE in Panc1 pancreatic adenocarcinoma cell line via upregulation of ORAI1 and STIM1. Altogether our
results reveal the novel calcium-dependent mechanism of action of the chemotherapy drugs 5-FU and
gemcitabine and emphasize the anti-apoptotic role of ORAI1 and STIM1 in pancreatic adenocarcinoma cells.
This article is part of a Special Issue entitled: Calcium signaling in health and disease. Guest Editors: Geert
Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic cancer and in particular pancreatic ductal adenocarcinoma
(PDAC) representing themost prevalent pancreatic neoplasm accounting
for about 90% of all pancreatic tumors [1,2], is one of the leading causes of
cancer death in men and women [3]. The current ﬁve-year relative sur-
vival rate is about 6% whereas most patients die within the one year fol-
lowing cancer detection [2]. One of the reasons of this is that early stage
pancreatic cancer usually has no symptoms and thus the majority of
cases are diagnosed at the late metastatic or invasive stages which are
not suitable for surgery. The lack of useful early stage diagnostic markers
and techniques further worsen the situation [2]. Furthermore, high resis-
tance of PDAC to conventional radiotherapy and chemotherapy treat-
ments contributes to the pessimistic prognosis of this disease [4–6].a; SOCE, store operated calcium
tromal interaction molecule 1;
endoplasmic reticulum Ca2+
signaling in health and disease.
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. Prevarskaya).Pancreatic cancer cells have been shown to exhibit a number of ge-
netic mutations leading to uncontrolled cell proliferation, acquisition
of metastatic potential as well as evasion of programmed cell death
(apoptosis) [7]. Apoptosis is a physiological process that is essential
for normal tissue homeostasis and deregulation of apoptotic machinery
has been shown to contribute to themalignant transformation. Evading
apoptosis represents one of the cancer hallmarks initially deﬁned by
Hanahan andWeinberg [8]. Indeed, resistance to apoptosis has been im-
plicated in moderate efﬁciency or failure of a number of anti-cancer
treatments. Thus, targeting apoptosis represents a promising strategy
in cancer treatments.
Numerous studies have emphasized the key role of calcium and
calcium-permeable ion channels in the regulation of apoptosis [9–12].
The store-operated calcium channels (SOCs) represent one of the
major calcium-entry pathways in non-excitable cells. SOCs and in par-
ticular their major components ORAI1 and STIM1 [13] have been
shown to be implicated in a number of physiological processes, includ-
ing proliferation, development, contraction and motility [14–19].
Moreover, recent studies suggest an important role for ORAI1 and
STIM1 in cancerogenesis. Both ORAI1 and STIM1 have been reported
to be involved in the regulation of apoptosis, proliferation, migration
and invasion in a number of human cancers, including prostate cancer,
breast cancer, cervical cancer and glioblastoma [12,20–28].
Herewe demonstrate that ORAI1 and STIM1mediate store-operated
calcium entry (SOCE) in pancreatic adenocarcinoma cell lines.We show
that both ORAI1 and STIM1 play pro-survival anti-apoptotic role in
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ORAI1 and/or STIM1 increases apoptosis induced by chemotherapy
drugs 5-ﬂuorouracil (5-FU) or gemcitabine. We also demonstrate that
both 5-FU and gemcitabine treatments increase SOCE in Panc1 pancre-
atic adenocarcinoma cell line via upregulation of ORAI1 and STIM1.
Altogether our results reveal the novel calcium-dependent mecha-
nism of action of the chemotherapy drugs 5-FU and gemcitabine and
emphasize the anti-apoptotic role of ORAI1 and STIM1 in pancreatic
adenocarcinoma cells.
2. Materials and methods
2.1. Antibodies and reagents
Mouse anti-ORAI1 (PM-5205, ProSci), mouse anti-STIM1 (610954,
BD Transduction), mouse anti-Actin (A5441, Sigma). 5-Fluorouracil
(5-FU) (F6627) was from Sigma. Gemcitabine (sc-204763A) was from
Santa Cruz Biotechnology. Thapsigargin (TG) (1138) was from Tocris.
2.2. Cell culture and transfection
Pancreatic adenocarcinoma cell line Panc1 from the American Type
Culture Collection (ATCC) was cultured in Dulbecco's minimal essential
medium DMEM + GlutaMAX (31966, Invitrogen, Life Technologies
Inc.) supplemented with 10% FCS (PAA Gold). Pancreatic adenocarcino-
ma cell lines ASPC1 and BxPC3 from the ATCC were cultured in RPMI
1640 medium (31870, Gibco-Life Technologies) supplemented with
5mM L-glutamine (25030, Gibco) and 10% FCS (PAA Gold). Pancreat-
ic adenocarcinoma cell line MiaPaca2 from the ATCC was cultured in
DMEM/F12 medium (31330, Gibco-Life Technologies) supplemented
with 2.5% Horse Serum (S 9135, Biochrom) and 10% FCS (PAA Gold).
Pancreatic adenocarcinoma cell line Capan1 from the ATCC was
cultured in IMDM medium (SH 30229.01 HyClone, Thermoscientiﬁc)
supplemented with 20% FCS (PAA Gold). Immortalized human pancre-
atic ductal epithelial cells H6C7 were obtained from Dr. Ming-Sound
Tsao and cultured in KBM medium (CC-3101, Lonza) supplemented
with KGM SingleQuots (CC-4131, Lonza). Cells were grown at 37 °C in
a humidiﬁed atmosphere containing 5% CO2.
Cells were transfected with 40 nM of siRNA against ORAI1, STIM1 or
both (Dharmacon Inc., Fremont, CA, USA) using Hyperfect transfection
reagent (Qiagen Inc.), following the manufacturer's instructions. siRNA
sequences were the following: CT: 5′-CUUACGCCUGAGUACUUCGA
(dTdT)-3′, hOrai1: 5′-UGAGCAACGUGCACAAUCU (dTdT)-3′, hSTIM1:
5′-GGCUCUGGAUACAGUGCUC (dTdT)-3′.
2.3. qRT-PCR
Total RNAwas extracted using TRI reagent (Sigma) and treatedwith
DNAse (Ambion). cDNA was synthesized by reverse transcription. qRT-
PCR was performed in a real-time thermal cycler Cfx C1000 (Bio-Rad)
using EvaGreen Supermix (Bio-Rad). Primers are listed in Table 1.
2.4. Western blotting
Cells were washed with cold PBS and lysed in ice-cold buffer
containing: 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 1% sodium
deoxycholate, 10 mM PO4Na2/K buffer, a protease inhibitor cocktailTable 1
List of primers used for qPCR.
No. Name Forward (5′-…-3′) Backward (5′-…-3′)
1 hSTIM1 TGTGGAGCTGCCTCAGTATG CTTCAGCACAGTCCCTGTCA
2 hOrai1 ATGGTGGCAATGGTGGAG CTGATCATGAGCGCAAACAG
3 GAPDH TTCGTCATGGCTGTGAACCA CAGTGATGCGCATGGACTGT(Sigma-Aldrich) and a phosphatase inhibitor cocktail PhosSTOP (Roche).
The lysates were centrifuged at 15,000 ×g at 4 °C for 15 min to remove
cell debris and supernatant protein concentration was determined by
the BCA protein assay kit (Pierce Biotechnology). 30 μg of total protein
was subjected to SDS-PAGE followed by transfer to PVDF membranes
using the Trans-Blot® SD semi-dry transfer cell (Bio-Rad). The
membranes were blocked in a 5% fat-free milk containing TNT buffer
(Tris–HCl, pH 7.5, 140 mM NaCl, and 0.05% Tween 20) for 1 h at room
temperature. The membranes were next incubated overnight at 4 °C
with primary antibodies, and then for 1 h at room temperature with
secondary antibodies conjugated to horseradish peroxidase. After wash-
ing, the membranes were processed for chemiluminescence detection
using Luminata Western HRP substrate (Milipore). Image J software
was employed for quantitative analysis.2.5. Calcium imaging
Pancreatic cancer cells were grown on glass coverslips to carry out
calcium imaging experiments. Ratiometric dye Fura-2/AM (F1221,
Invitrogen) was used as a Ca2+ indicator. Cells were loaded with 2 μM
Fura-2/AM for 45 min at 37 °C and 5%CO2 in corresponding medium
and subsequentlywashed three timeswith external solution containing
(inmM): 140NaCl, 5 KCl, 1MgCl2, 2 CaCl2, 5 glucose, 10 hepes (pH 7.4).
The coverslip was then transferred in a perfusion chamber on the stage
of Nikon Eclipse Ti microscope. Fluorescence was alternatively excited
at 340 and 380 nm with a monochromator (Polychrome IV, TILL
Photonics Gmbh) and captured at 510 nm by a QImaging CCD camera
(QImaging). Acquisition and analysiswere performedwith theMetaFluor
7.7.5.0 software (Molecular Devices Corp.).2.6. Apoptosis assays
The level of apoptosis was determined by Hoechst staining. Cells
were grown on 6-well plates and transfected with siCT, siORAI1 or
siSTIM1. In 24 h cell were subjected to chemotherapy treatments for
another 72 h. At the end of the treatments, both ﬂoating and attached
cells were collected by trypsinization, centrifuged and resuspended in
1 ml of phosphate-buffered saline (PBS). Following cytospin cells were
ﬁxed with ice-cold methanol for 10 min, washed with PBS and stained
with 5 μg/ml Hoescht 33258 for 10 min at room temperature. Cells
were then washed twice with PBS, mounted in glycerogel (DAKO)
and subjected to ﬂuorescence microscopy analysis. Nuclear mor-
phology was displayed on Zeiss Axio Imager A1 ﬂuorescence micro-
scope (405–435nm). The percentage of apoptotic cells (with condensed/
fragmented nuclei) was determined by counting at least 500 cells in ran-
dom ﬁelds.
Alternatively, apoptotic cells were detected by Alexa Fluor® 488
Annexin V/Propidium iodide double staining. At the end of the treat-
ments, both ﬂoating and attached cells were collected by trypsinization,
centrifuged, washed with PBS and stained with Alexa Fluor® 488
Annexin V and Propidium iodide according to the manufacturer's
instructions (Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit, Life
Technologies). Cells were examined by ﬂuorescence microscopy on
Zeiss Axio Imager A1 microscope. The percentage of Alexa Fluor® 488
Annexin V-positive cells was determined by counting at least 500 cells
in random ﬁelds.2.7. Data analysis
Data were analyzed using Origin 7.0 (Microcal Software). Statistical
analysis was performed using Student's t-test, and p b 0.05 was
considered as signiﬁcant. Asterisks denote: *p b 0.05, **p b 0.01 and
***p b 0.001.
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3.1. ORAI1 and STIM1 are differentially expressed in pancreatic cancer cells
Although both ORAI1 and STIM1 have been previously shown to
be expressed in a variety of cell types, the information about their ex-
pression in PDAC cell lines is missing. Therefore, we ﬁrst sought to
examine if they are present in several available PDAC cell lines, namely
Capan1, ASPC1, Panc1, MiaPaca2 and BxPC3 as well as in “normal” im-
mortalized human pancreatic ductal epithelial cells H6C7. By using
qRT-PCR technique we found that ORAI1 and STIM1 are differentially
expressed in all the cell lines tested (Fig. 1A). Further, we characterized
the expression of ORAI1 and STIM1 on the protein level by Western
blotting. We found that both ORAI1 and STIM1 are expressed on the
protein level in all the cell lines and the levels of their expression differ
between the cell lines, which correlates well with qRT-PCR data (Fig. 1B
and C). For the subsequent experiments, we decided to focus on Panc1
cell line, as it is characterized by relatively high levels of ORAI1 and
STIM1 expression.Fig. 1. ORAI1 and STIM1 are differentially expressed in pancreatic cancer cells. (A) qRT-PCR de
BxPC3 cell lines. Expression levels of ORAI1 and STIM1 relative to GAPDH for each cell line we
n = 3. (B) Western blot showing the expression of ORAI1 in H6C7, Capan1, ASPC1, Panc1, Mia
Actin are shown. Bar plot shows the quantiﬁcation of the protein expression levels of ORAI1 rel
as means ± S.D. n = 3. (C) Western blot showing the expression of STIM1 in H6C7, Capan1, A
STIM1 relative to Actin are shown. Bar plot shows the quantiﬁcation of the protein expression
line. Data is represented as means ± S.D. n = 3.3.2. ORAI1 and STIM1 are involved in SOCE in pancreatic cancer cells
Numerous reports demonstrated that ORAI1 and STIM1 mediate
calcium release-activated channel (CRAC) activity and thus SOCE in a
variety of cell types. Given that this function of ORAI1 and STIM1
has never been demonstrated in PDAC cells, we next investigated if
ORAI1 and STIM1 are involved in SOCE in these cells by using siRNA-
approach. Panc1 cells were transfected with siCT, siORAI1 or siSTIM1.
We determined the efﬁciency of siRNA transfections in 48 h on mRNA
and protein levels by using qRT-PCR and Western blotting techniques
respectively (Fig. 2C and D). 48 h following siRNA transfection we
tried to record IP3-induced CRAC activity by performing electrophysio-
logical experiments in Panc1 cells. In most cases IP3 dialysis did not
induce any recordable CRAC current, thus precluding any statistical
analysis of the effect of ORAI1/STIM1 knockdown. Therefore, we
moved to an approach based on calcium imaging using Fura2/AM
probe. 48 h following siRNA transfection cells were loaded with Fura2/
AM probe and subjected to calcium imaging experiment. We checked
whether siRNA-mediated knockdown of ORAI1 or STIM1 inﬂuencestection of expression of ORAI1 and STIM1 in H6C7, Capan1, ASPC1, Panc1, MiaPaca2 and
re normalized to ORAI1 level in “normal” H6C7 cell line. Data presented as means ± S.D.
Paca2 and BxPC3 cell lines. Densitometric quantitations for normalized ORAI1 relative to
ative to Actin for each cell line normalized to ORAI1 level in H6C7 cell line. Data presented
SPC1, Panc1, MiaPaca2 and BxPC3 cell lines. Densitometric quantitations for normalized
levels of STIM1 relative to Actin for each cell line normalized to STIM1 level in H6C7 cell
Fig. 2.ORAI1 and STIM1are involved in SOCE in PDAC cells. (A) KnockdownofORAI1 or STIM1 inhibits SOCE in Panc1 cells. Panc1 cellswere transfectedwith siCT, siORAI1 or siSTIM1. In 48
h cells were loaded with Fura2/AM probe and subjected to calcium imaging experiment. TG-induced SOCE was analyzed. (B) Quantiﬁcation of the TG-induced SOCE amplitude in cells
transfected with siCT, siORAI1 or siSTIM1. n = 5 (C) qRT-PCR detection of expression of ORAI1 and STIM1 in Panc1 cells 48 h after transfection with siORAI1 and siSTIM1 respectively.
(D) Western blot showing the expression of ORAI1 and STIM1 in siCT-, siORAI1- or siSTIM1-transfected Panc1 cells 48 h after transfection. Densitometric quantitations for normalized
ORAI1 and STIM1 relative to Actin are shown.
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itor of sarco/endoplasmic reticulumCa2+-ATPase (SERCA).More specif-
ically, intracellular storeswere depleted by TG in nominally calcium free
extracellular saline followed by addition of 2 mM Ca2+ to the cells to
initiate the inﬂux via store-operated calcium channels. When this
assay was performed on siORAI1- or siSTIM1-transfected Panc1 cells,
calcium entry was signiﬁcantly reduced (Fig. 2A and B). Further,
ORAI1 and STIM1 knockdown also caused a decrease in SOCE in other
cell lines tested, namely ASPC1, MiaPaca2 and Capan1 (Fig. S1A, S1B
and S1C). These results suggested that ORAI1 and STIM1 mediate
SOCE in PDAC cell lines. In addition, TG-stimulated calcium entry
was completely inhibited by La3+ (10 μM), Gd3+ (10 μM) or BTP2
(10 μM), exhibiting pharmacological properties characteristic of SOCE
(Fig. S2A and S2B).Fig. 3.Downregulation of ORAI1 and STIM1 sensitizes Panc1 cells to chemotherapy treatments
were treatedwith chemotherapy drugs 5-FU or gemcitabine (GB) for 72 h. At the end of the trea
analysis of nuclear morphology. Data is represented as means ± S.D. n = 3. (B) Cells were tran
5-FU or gemcitabine for 72 h. At the end of the treatment cells were collected, stainedwith A
means ± S.D. n = 3.3.3. Downregulation of ORAI1 and STIM1 sensitizes Panc1 cells to
chemotherapy treatments
Previous reports indicated that ORAI1, STIM1 aswell as SOCEplay an
important role in cell physiology and pathology. In particular, their role
in apoptosis regulation has been extensively studied in different cell
types. Therefore,we next investigatedwhether ORAI1 and STIM1 are in-
volved in apoptosis regulation in Panc1 cells. Cells were transfected
with siCT, siORAI1, siSTIM1 or siORAI1 + siSTIM1. In 24 h cells were
left untreated or treated with chemotherapy drugs 5-FU (50 μM) or
gemcitabine (50 μM) for 72 h to induce apoptosis. At the end of treat-
ments cells were collected, stained with Hoechst 33258 dye and sub-
jected to ﬂuorescence microscopy analysis of nuclear morphology.
Alternatively, apoptotic cells were detected by Annexin V/PI staining.. (A) Cells were transfected with siCT, siORAI1, siSTIM1 or siORAI1 + siSTIM1. In 24 h cells
tment cellswere collected, stainedwith Hoechst and subjected to ﬂuorescencemicroscopy
sfected with siCT, siORAI1 or siSTIM1. In 24 h cells were treated with chemotherapy drugs
nnexin V/PI and subjected to ﬂuorescencemicroscopy analysis. Data is represented as
2267K. Kondratska et al. / Biochimica et Biophysica Acta 1843 (2014) 2263–2269Downregulation of ORAI1 or/and STIM1 did not induce signiﬁcant
changes to the basal level of apoptosis in untreated cells (Fig. 3A and
B). However, when cells were treated with 5-FU or gemcitabine,
the downregulation of ORAI1 or/and STIM1 increased the levels of apo-
ptosis induced by these drugs (Fig. 3A and B). These results suggested
that ORAI1 and STIM1 play pro-survival anti-apoptotic role in Panc1
cells.
3.4. Chemotherapy drugs 5-FU and gemcitabine increase SOCE in
Panc1 cells
The regulation of chemotherapy-induced apoptosis by ORAI1 and
STIM1 suggests that apparently there is a link between chemotherapy
drugs and Ca2+-homeostasis. To test this assumption we incubated
Panc1 cells in basal medium with or without chemotherapy agents
(5-FU (50 μM) or gemcitabine (50 μM)) for 24 h. At the end of the treat-
ment cells were loaded with Fura2/AM probe and subjected to calcium
imaging experiment. We tested whether chemotherapy treatments
inﬂuence cytosolic calcium levels in Panc1 cells using the same TG-
based approach as described above. Interestingly, we have found that
both 5-FU and gemcitabine treatments signiﬁcantly increased SOCE in
these cells (Fig. 4A and B). We hypothesized that this effect can be
the consequence of the increase in expression levels of SOCs by chemo-
therapy agents. To test this hypothesis, we next assessed the expression
levels of ORAI1 and STIM1 following 24 h treatment with 5-FU or
gemcitabine. 5-FU and gemcitabine signiﬁcantly increased the expres-
sion of ORAI1 and STIM1 on both mRNA and protein levels (Fig. 4C
and D). These results correlate well with calcium imaging data
(Fig. 4A and B), suggesting that chemotherapy agents 5-FU andFig. 4. Chemotherapy drugs 5-FU and gemcitabine (GB) increase SOCE in Panc1 cells. (A) 5-FU
5-FU for 24h. At the end of the treatment cellswere loadedwith Fura2/AMprobe and subjected
of the TG-induced SOCE amplitude. n= 4. (B) Gemcitabine increases SOCE in Panc1 cells. Panc1
the treatment cells were loadedwith Fura2/AM probe and subjected to calcium imaging experi
amplitude. n = 4. (C) 5-FU and gemcitabine upregulate ORAI1 and STIM1mRNAs in Panc1 cell
ment with 5-FU or gemcitabine. (D) 5-FU and gemcitabine upregulate ORAI1 and STIM1 on the
Panc1 cells following 48h treatmentwith 5-FU or gemcitabine. Densitometric quantitations for
of the normalized expression levels of ORAI1 and STIM1 relative to Actin. Data presented as mgemcitabine can inﬂuence cytosolic calcium levels by upregulation of
ORAI1 and STIM1.
4. Discussion
In this study, we provide evidence that ORAI1 and STIM1 mediate
SOCE in pancreatic adenocarcinoma cell lines. We show that both
ORAI1 and STIM1 play pro-survival anti-apoptotic role in pancreatic
adenocarcinoma cell lines, as siRNA-mediated knockdown of
ORAI1 and/or STIM1 increases apoptosis induced by chemotherapy
drugs 5-FU or gemcitabine. We also demonstrate that both 5-FU
and gemcitabine treatments increase SOCE in Panc1 pancreatic
adenocarcinoma cell line apparently via upregulation of ORAI1 and
STIM1.
Numerous studies demonstrate the important role of SOCE in a
plethora of cellular processes and functions in different cell types, in-
cluding endothelial cell proliferation [15], smooth muscle migration
[16,17] and skeletal muscle development and contraction [18]. More-
over, SOCE has been implicated in a number of pathological processes
typical for cancer, such as breast tumor cell migration and metastasis
[29], human glioblastoma invasion [26] and apoptosis in a variety of
cell types [22–24,30]. Therefore, the identiﬁcation of the molecular
nature of SOCs in PDAC is of great importance as it can reveal novel
approaches for treating pancreatic cancer through targeting SOCE-
dependent processes.
The evidence presented here clearly demonstrates that ORAI1 and
STIM1 are expressed in ﬁve PDAC cell line tested namely Capan1,
ASPC1, Panc1, MiaPaca2 and BxPC3 as well as in “normal” human pan-
creatic ductal epithelial cells H6C7. It should be noted, that “normal”increase SOCE in Panc1 cells. Panc1 cells were incubated in basal mediumwith or without
to calcium imaging experiment. TG-inducedSOCEwas analyzed. Inset shows quantiﬁcation
cells were incubated in basal mediumwith orwithout gemcitabine for 24 h. At the end of
ment. TG-induced SOCE was analyzed. Inset shows quantiﬁcation of the TG-induced SOCE
s. qRT-PCR detection of expression of ORAI1 and STIM1 in Panc1 cells following 48 h treat-
protein level in Panc1 cells. Western blot showing the expression of ORAI1 and STIM1 in
normalizedORAI1 and STIM1 relative to Actin are shown. Bar plots show the quantiﬁcation
eans ± S.D. n = 3.
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compared to several cancer cell lines, in particular Capan1 and Panc1.
This result indirectly suggests that these cancer cells upregulate ORAI1
and STIM1 to protect themselves against apoptosis.
Interestingly, despite the suggested important role of SOCs in the
regulation of apoptosis, metastasis and invasion in different cancers
[22–24,26,29,30], their role in PDAC cells have never been studied.
Our results revealed the anti-apoptotic role of ORAI1 and STIM1 in
Panc1 cells. We showed that siRNA-mediated knockdown of ORAI1
and/or STIM1 increases apoptosis induced by 5-FU or gemcitabine in
Panc1 cells.
Previous studies reported conﬂicting results in regard to the role of
SOCE, ORAI1 and STIM1 in apoptosis regulation. Some reports suggest
that SOCE, ORAI1 as well as STIM1 contribute to apoptosis induced by
various stress stimuli [22,30], while others demonstrate their pro-
survival anti-apoptotic role [23,24,31]. Indeed, ORAI1 was reported to
contribute to the establishment of an apoptosis-resistant phenotype in
prostate cancer cells and ORAI1 knockdown protected LNCaP cells
against TG- or oxaliplatin/cisplatin-induced apoptosis [22]. In line with
this, pharmacological SOCE inhibition or STIM1 knockdown was dem-
onstrated to inhibit hydrogen peroxide-induced apoptosis in HT22
cells via alleviation of intracellular Ca2+ overload, restoration of the
mitochondrial membrane potential and decrease of cytochrome C re-
lease [32]. In contrast, pharmacological inhibition of SOCE or STIM1
downregulation was shown to enhance apoptosis induced by cisplatin
in non-small cell lung cancer cells [31]. Further, it was reported that
Orai1-driven Ca2+-entry delays the induction of the CD95-mediated
apoptotic signal in leukemic T-cell lines through the translocation of
the Ca2+-dependent protein kinase C (PKC) β2 to the death-inducing
signaling complex and its subsequent inactivation in T-cells. This
prevented CD95-mediated caspase activation and delayed delivery of
the apoptotic signal [23].
Although it seems that these studies represent contradictory results,
there are several clues which can explain this discrepancy. First, it is
well known that different cells are characterized by a different set and
level of expressed genes, in particular ORAI1 and STIM1 [14]. Thus, the
contradiction could arise from the different cell types used in these
studies. Second, both ORAI1 and STIM1 were shown to regulate the
activity of a number of intracellular effectors including PKC β2 [23],
PKC δ [33], extracellular signal-related kinases 1 and 2 (ERK 1/2)
[34], calpains as well as cytoplasmic kinase Pyk2 [21]. Further, the
expression/function of ORAI1 and STIM1 was reported to be regulated
by several protein kinases, such as serum and glucocorticoid-inducible
kinase 1 (SGK1) and AMP activated kinase (AMPK) [35], by transcrip-
tion factor nuclear factor κB (NF-κB) [36] as well as by cytoskeleton re-
organization [37]. Moreover, both ORAI1 and STIM1 were shown to
have SOCE independent functions. It was reported that ORAI1 could
stimulate mammary tumorigenesis by store- and STIM1-independent
pathway involving secretory pathway Ca2+-ATPase, SPCA2 [38]. Like-
wise, STIM1 was suggested to be a general stress sensor [39] capable
of interacting with multiple molecular targets, including ORAI1 [13],
TRPC1 [40] and Cav1.2 channels [41]. Considering such a complex regu-
latory network and the proven role for many of ORAI1/STIM1 targets in
both pro-survival and pro-apoptotic processes, the role of SOCE, ORAI1
and STIM1 in each particular cell type could differ depending on the
signaling pathway activated.
We noticed that STIM1-knockdown increased chemotherapy-
induced apoptosis more effectively than ORAI1-knockdown, although
the difference did not reach statistical signiﬁcance. This result points
to the potential ORAI1-independent role of STIM1 in apoptosis regula-
tion in Panc1 cells.
Further, the effect of ORAI1- and/or STIM1-knockdown on apoptosis
in Panc1 cells was more pronounced in the case of treatment with
gemcitabine compared to 5-FU. This result could point to increased
calcium-dependency of gemcitabine mechanisms of action compared
to 5-FU.Interestingly, our results also suggest that both 5-FU and gemcitabine
could affect intracellular calcium homeostasis. Indeed, both 5-FU and
gemcitabine treatments increase SOCE in Panc1 cells and upregulate
ORAI1 and STIM1. This result suggests that chemotherapy treatments
could have calcium-dependent effects, which are unrelated to the prima-
ry DNA-targeting mechanisms of their action. Moreover, these calcium
dependent effects could potentially contribute to the ﬁnal efﬁcacy of the
drugs in cancer therapy. Further experiments are needed to understand
the mechanism of this effect. We hypothesize that during chemotherapy
treatments cells upregulate SOCs to resist apoptosis. Thus, the downregu-
lation of SOCs in these conditions makes cells more sensitive to apoptosis
induction.
In conclusion, given the important role of ORAI1 and STIM1 in a
number of cellular processes and functions in different cell types, they
could be potentially considered as a promising target in anti-cancer
therapy. However, the vast heterogeneity in the reported roles for
ORAI1 and STIM1 in different cell types conﬁrms that their ﬁnal effect
on apoptosis could depend on multiple factors, such as cell type, nutri-
ent and growth factor availability, pathology (cancer, inﬂammation,
etc.) as well as intracellular signaling pathways involved. Therefore,
future research is indispensable to better understand the speciﬁc
mechanisms of apoptosis regulation by SOCE, ORAI1 and STIM1 to
ﬁnally conclude if their modulators could be effective in cancer treat-
ment in each particular case.
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